The apolipoprotein E ε3 Christchurch variant provides remarkable resilience against Alzheimer disease by limiting tau propagation and suppressing neuroinflammation. New research reveals that this protection extends to the periphery, where ‘lipid-loaded’ extracellular vesicles stabilize the blood–brain barrier, which offers a novel systemic mechanism for developing potent disease-modifying therapies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680–1683 (2019).
Quiroz, Y. T. et al. APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer’s disease. N. Engl. J. Med. 390, 2156–2164 (2024).
Martens, Y. A. et al. ApoE cascade hypothesis in the pathogenesis of Alzheimer’s disease and related dementias. Neuron 110, 1304–1317 (2022).
Chen, Y. et al. APOE3ch alters microglial response and suppresses Aβ-induced tau seeding and spread. Cell 187, 428–445 (2024).
Guo, J. L. et al. Decreased lipidated ApoE-receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes. Cell 188, 187–206 (2025).
Naguib, S. et al. The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway. Immunity 58, 1931–1947.e9 (2025).
Pineda-Lopez, L. et al. Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer’s disease. Alzheimers Dement. 22, e71148 (2026).
Tran, K. A. et al. Endothelial β-catenin signaling is required for maintaining adult blood-brain barrier integrity and central nervous system homeostasis. Circulation 133, 177–186 (2016).
Liu, C.-C. et al. Peripheral apoE4 enhances Alzheimer’s pathology and impairs cognition by compromising cerebrovascular function. Nat. Neurosci. 25, 1020–1033 (2022).
Günaydin, C. et al. AAVrh.10 delivery of novel APOE2-Christchurch variant suppresses amyloid and Tau pathology in Alzheimer’s disease mice. Mol. Ther. 32, 4303–4318 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G.B. is the editor-in-chief of Molecular Neurodegeneration and Molecular Neurodegeneration Advances, an associate editor for Science Advances, and is on the editorial board for Neuron. K.W. declares no competing interests.
Rights and permissions
About this article
Cite this article
Wang, K., Bu, G. Alzheimer disease protection from the periphery. Nat Rev Neurol (2026). https://doi.org/10.1038/s41582-026-01211-0
Published:
Version of record:
DOI: https://doi.org/10.1038/s41582-026-01211-0
